The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read More
Novartis’ Rydapt , the first and only targeted therapy approved in Europe for FLT3-mutated acute myeloid leukaemia (AML), has been rejected for NHS use by the National Institute for Health and Care Excellence.
Read More
The European Commission has approved Novartis’ Rydapt to treat a certain form of acute myeloid leukaemia (AML) as well as three other rare diseases.
Read More
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
